You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVoriconazole
Accession NumberDB00582  (APRD00543)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Voriconazole (Vfend®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.

Structure
Thumb
Synonyms
SynonymLanguageCode
(AlphaR,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolNot AvailableNot Available
(R-(R*,s*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolNot AvailableNot Available
VCZNot AvailableNot Available
VfendNot AvailableNot Available
VoriconazolNot AvailableNot Available
VoriconazolumNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vfendpowder, for suspension40 mg/mLoralRoerig2003-03-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendtablet, film coated50 mgoralRoerig2003-03-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendtablet, film coated200 mgoralRoerig2003-03-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2002-05-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2003-03-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2012-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2012-10-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendtablet, film coated200 mgoralCardinal Health2002-05-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendtablet, film coated50 mgoralCardinal Health2002-05-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated50 mgoralGreenstone LLC2002-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralGreenstone LLC2002-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazolepowder, for suspension40 mg/mLoralGreenstone LLC2013-12-16Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Vfendtablet50 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vfendtablet200 mgoralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Vfendpowder for suspension3 goralPfizer Canada IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Voriconazoletablet, film coated50 mgoralTeva Pharmaceuticals USA Inc2012-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralTeva Pharmaceuticals USA Inc2012-06-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated50 mgoralMylan Pharmaceuticals Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralMylan Pharmaceuticals Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazolepowder, for suspension40 mg/mLoralMylan Pharmaceuticals Inc.2013-09-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoleinjection, powder, lyophilized, for solution10 mg/mLintravenousSandoz Inc2012-05-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated50 mgoralSandoz Inc2011-12-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralSandoz Inc2011-12-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralCardinal Health2012-09-21Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated200 mgoralAmerican Health Packaging2012-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Voriconazoletablet, film coated50 mgoralAmerican Health Packaging2014-01-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
CAS number137234-62-9
WeightAverage: 349.3105
Monoisotopic: 349.11504471
Chemical FormulaC16H14F3N5O
InChI KeyBCEHBSKCWLPMDN-MGPLVRAMSA-N
InChI
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
IUPAC Name
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
SMILES
C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenylpropane
  • Halopyrimidine
  • Halobenzene
  • Fluorobenzene
  • Pyrimidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Tertiary alcohol
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
PharmacodynamicsVoriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth.
Mechanism of actionVoriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.
AbsorptionThe oral bioavailability is estimated to be 96% (CV 13%).
Volume of distribution
  • 4.6 L/kg
Protein binding58%
Metabolism

Hepatic. The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. Since this metabolite has minimal antifungal activity, it does not contribute to the overall efficacy of voriconazole.

SubstrateEnzymesProduct
Voriconazole
UK-121,265 (Voriconazole N-oxide)Details
Voriconazole
4-HydroxyvoriconazoleDetails
4-Hydroxyvoriconazole
Not Available
4-Hydroxyvoriconazole 4-O-glucuronideDetails
UK-121,265 (Voriconazole N-oxide)
Not Available
UK-51,060Details
UK-51,060
Not Available
UK-215,364Details
UK-215,364
Not Available
Voriconazole O-glucuronide derivative (1)Details
Route of eliminationVoriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityThe minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.
Affected organisms
  • Yeast and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9047
Caco-2 permeable+0.7219
P-glycoprotein substrateSubstrate0.591
P-glycoprotein inhibitor INon-inhibitor0.6113
P-glycoprotein inhibitor IINon-inhibitor0.8195
Renal organic cation transporterNon-inhibitor0.5354
CYP450 2C9 substrateNon-substrate0.727
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5792
CYP450 1A2 substrateNon-inhibitor0.7491
CYP450 2C9 substrateInhibitor0.5203
CYP450 2D6 substrateNon-inhibitor0.8315
CYP450 2C19 substrateInhibitor0.5784
CYP450 3A4 substrateNon-inhibitor0.7011
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6649
Ames testNon AMES toxic0.7019
CarcinogenicityNon-carcinogens0.776
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3469 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8791
hERG inhibition (predictor II)Non-inhibitor0.6282
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous10 mg/mL
Powder for suspensionoral3 g
Powder, for suspensionoral40 mg/mL
Tabletoral200 mg
Tabletoral50 mg
Tablet, film coatedoral200 mg
Tablet, film coatedoral50 mg
Prices
Unit descriptionCostUnit
Vfend 40 mg/ml Suspension 75ml Bottle870.72USD bottle
Vfend iv 200 mg vial143.5USD vial
Vfend 200 mg tablet49.74USD tablet
Vfend 50 mg tablet12.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada20353142000-01-182011-01-30
Canada22950352005-04-192018-06-02
United States51168441992-08-112009-08-11
United States66328031998-06-022018-06-02
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point127-130 °CNot Available
water solubilityLowNot Available
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0978 mg/mLALOGPS
logP1.65ALOGPS
logP1.82ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.71ChemAxon
pKa (Strongest Basic)2.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.28 m3·mol-1ChemAxon
Polarizability30.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Venkataraman Sundaram, Venkata Bhaskara Rao Uppala, Surya Prabhakar Akundi, Venkateswarlu Muvva, Vijayawardhan Chitta, Alekhya Donthula, Manoj Ramesh Kharkar, Surya Narayana Devarakonda, Subba Reddy Peddireddy, “Process For Preparing Voriconazole.” U.S. Patent US20080194820, issued August 14, 2008.

US20080194820
General Reference
  1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15. Pubmed
  2. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005 Nov 15;41(10):1448-52. Epub 2005 Oct 13. Pubmed
  3. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 Oct 22-28;366(9495):1435-42. Pubmed
  4. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001 Nov 1;33(9):1447-54. Epub 2001 Sep 26. Pubmed
  5. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225-34. Pubmed
External Links
ATC CodesJ02AC03
AHFS Codes
  • 08:14.08
PDB EntriesNot Available
FDA labelDownload (321 KB)
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolMay increase the serum concentration of Vitamin K Antagonists.
ado-trastuzumab emtansineCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.
AlfuzosinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.
AlmotriptanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.
AlosetronCYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.
AmlodipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
AmobarbitalBarbiturates may decrease the serum concentration of Voriconazole.
Amphotericin BAntifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.
AmrinoneAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
ApixabanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.
AripiprazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.
AstemizoleVoriconazole may increase the serum concentration of Astemizole.
AtazanavirMay decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir.
AtorvastatinVoriconazole may increase the serum concentration of AtorvaSTATin.
AvanafilVoriconazole may increase the serum concentration of Avanafil.
AxitinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.
BedaquilineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.
BepridilAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
BoceprevirMay increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir.
BortezomibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.
BosentanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan.
BosutinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.
Brentuximab vedotinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.
BrinzolamideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.
BuspironeAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone. Isavuconazonium considerations are addressed in separate monographs.
BusulfanAntifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs.
ButabarbitalBarbiturates may decrease the serum concentration of Voriconazole.
ButalbitalBarbiturates may decrease the serum concentration of Voriconazole.
ButethalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
CabazitaxelCYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.
CabozantinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.
CarbamazepineCarBAMazepine may decrease the serum concentration of Voriconazole.
CarvedilolCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.
ChloramphenicolChloramphenicol may increase the serum concentration of Voriconazole.
ChlorpropamideMay increase the serum concentration of Sulfonylureas.
CilostazolCYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.
CisaprideAntifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs.
ClopidogrelCYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.
ColchicineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.
ConivaptanAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Fluconazole and isavuconazonium considerations are addressed in separate monographs.
CrizotinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.
DabrafenibMay decrease the serum concentration of CYP2C9 Substrates.
DapoxetineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine.
DarunavirMay decrease the serum concentration of Voriconazole.
DasatinibVoriconazole may enhance the QTc-prolonging effect of Dasatinib. Voriconazole may increase the serum concentration of Dasatinib.
DesogestrelMay decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.
DidanosineMay decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.
DihydroergotamineMay increase the serum concentration of Dihydroergotamine.
DocetaxelAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel. Fluconazole and isavuconazonium considerations are addressed in separate monographs.
DofetilideAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.
DomperidoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone.
DronabinolCYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol.
DronedaroneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.
DrospirenoneMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
DutasterideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.
EfavirenzMay decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Efavirenz.
EletriptanMay increase the serum concentration of Eletriptan.
EnzalutamideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.
EplerenoneVoriconazole may increase the serum concentration of Eplerenone.
Ergoloid mesylateMay increase the serum concentration of Ergoloid Mesylates.
ErgonovineVoriconazole may increase the serum concentration of Ergonovine.
ErgotamineVoriconazole may increase the serum concentration of Ergotamine.
ErlotinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.
EsomeprazoleMay increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.
EthynodiolMay decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.
EtonogestrelMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
EtravirineMay decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs.
EverolimusVoriconazole may increase the serum concentration of Everolimus.
FelodipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
FentanylCYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.
FesoterodineCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.
FluconazoleFluconazole may increase the serum concentration of Voriconazole.
FlunarizineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
FosamprenavirVoriconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole.
FosphenytoinMay decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.
GabapentinAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
GliclazideMay increase the serum concentration of Sulfonylureas.
GlimepirideMay increase the serum concentration of Sulfonylureas.
GlipizideMay increase the serum concentration of Sulfonylureas.
GlyburideMay increase the serum concentration of Sulfonylureas.
GuanfacineCYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.
HalofantrineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.
HeptabarbitalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
HexobarbitalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
HydrocodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Hydrocodone.
IbuprofenVoriconazole may increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.
IfosfamideCYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.
ImatinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib.
IrinotecanCYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan.
IsradipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
IvacaftorCYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.
IxabepiloneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.
LacosamideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide.
LamotrigineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
LansoprazoleProton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.
LapatinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.
LercanidipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
LevobupivacaineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine.
LevomilnacipranCYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.
LevonorgestrelMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
LomitapideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.
LopinavirMay decrease the serum concentration of Voriconazole.
LosartanAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan. Applicable Isavuconazonium considerations are addressed in separate monographs.
LovastatinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.
LULICONAZOLEMay increase the serum concentration of CYP2C19 Substrates.
LurasidoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.
MACITENTANCYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan.
Magnesium SulfateAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
MaravirocCYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.
Medroxyprogesterone AcetateMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
MeloxicamVoriconazole may increase the serum concentration of Meloxicam.
MestranolMay decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.
MethadoneMay increase the serum concentration of Methadone.
MethohexitalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
MethylergometrineMay increase the serum concentration of Methylergonovine.
MethylprednisoloneCYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.
MifepristoneMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
NelfinavirMay increase the serum concentration of Nelfinavir.
NevirapineMay increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole.
NicardipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
NilotinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.
NimodipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
NisoldipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
NitrendipineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
NorelgestrominMay decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.
NorethindroneMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
NorgestimateMay increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.
OmeprazoleProton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.
OspemifeneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.
OxybutyninCYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin.
OxycodoneMay enhance the adverse/toxic effect of OxyCODONE. Voriconazole may increase the serum concentration of OxyCODONE.
PanobinostatCYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.
PantoprazoleProton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.
ParicalcitolCYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.
PazopanibCYP3A4 Inhibitors (Strong) may increase the serum concentration of PAZOPanib.
PentobarbitalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
PerhexilineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
PhenobarbitalBarbiturates may decrease the serum concentration of Voriconazole.
PhenytoinMay decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.
PimecrolimusCYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.
PimozideAntifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias. Applicable Isavuconazonium considerations are addressed in separate monographs.
PonatinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.
PorfimerPhotosensitizing Agents may enhance the photosensitizing effect of Porfimer.
PranlukastCYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast.
PrasugrelCYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.
PrednisoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE.
PrenylamineAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
PrimidoneMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
QuinidineAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs.
RabeprazoleProton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.
RanolazineAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs.
RegorafenibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.
RepaglinideCYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide.
RetapamulinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.
RifampicinMay increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.
RifapentineMay increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.
RilpivirineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine.
RisedronateAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
RitonavirRitonavir may decrease the serum concentration of Voriconazole.
RivaroxabanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. For clarithromycin, refer to more specific clarithromycin-rivaroxaban monograph recommendations.
RuxolitinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.
SalmeterolCYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.
SaxagliptinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.
SecobarbitalMay decrease the serum concentration of Voriconazole. Exceptions: Methohexital; PENTobarbital; Secobarbital; Thiopental.
SildenafilMay increase the serum concentration of Sildenafil.
SilodosinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.
SimeprevirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir.
SimvastatinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.
SirolimusVoriconazole may increase the serum concentration of Sirolimus.
SolifenacinAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.
SucralfateMay decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).
SunitinibAntifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.
SuvorexantCYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant.
TadalafilVoriconazole may increase the serum concentration of Tadalafil.
TamsulosinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.
TelaprevirMay decrease the serum concentration of Voriconazole. Telaprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Telaprevir.
TerfenadineVoriconazole may increase the serum concentration of Terfenadine.
TicagrelorCYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.
TofacitinibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.
TolazamideMay increase the serum concentration of Sulfonylureas.
TolterodineCYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.
TolvaptanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.
ToremifeneCYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.
TrabectedinCYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin.
UlipristalCYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.
VardenafilVoriconazole may increase the serum concentration of Vardenafil.
VemurafenibCYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.
VenlafaxineMay enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.
VerapamilAntifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.
VerteporfinPhotosensitizing Agents may enhance the photosensitizing effect of Verteporfin.
VilazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.
VinblastineMay enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).
VincristineMay enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).
VinorelbineMay enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).
VorapaxarCYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar.
ZolpidemAntifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem. Applicable Isavuconazonium considerations are addressed in separate monographs.
ZopicloneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.
Food InteractionsNot Available

Targets

1. Lanosterol 14-alpha demethylase

Kind: protein

Organism: Yeast

Pharmacological action: yes

Actions: antagonist inhibitor

Components

Name UniProt ID Details
Lanosterol 14-alpha demethylase P10613 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. Epub 2003 Feb 26. Pubmed
  4. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G: Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005 Feb;49(2):668-79. Pubmed
  5. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4. Pubmed
  6. Thompson GR 3rd, Lewis JS 2nd: Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):83-94. Pubmed
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed
  8. Xu Y, Sheng C, Wang W, Che X, Cao Y, Dong G, Wang S, Ji H, Miao Z, Yao J, Zhang W: Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives. Bioorg Med Chem Lett. 2010 May 1;20(9):2942-5. Epub 2010 Mar 7. Pubmed
  9. Xu J, Cao Y, Zhang J, Yu S, Zou Y, Chai X, Wu Q, Zhang D, Jiang Y, Sun Q: Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives. Eur J Med Chem. 2011 Jul;46(7):3142-8. Epub 2011 Feb 24. Pubmed

Enzymes

1. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Dimethylaniline monooxygenase [N-oxide-forming] 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dimethylaniline monooxygenase [N-oxide-forming] 1 Q01740 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

5. Dimethylaniline monooxygenase [N-oxide-forming] 3

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dimethylaniline monooxygenase [N-oxide-forming] 3 P31513 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

6. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

7. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

8. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11